ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

178    www.ecfs.eu OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS EVALUATION AND MANAGEMENT OF BETA-LACTAM ANTIBIOTIC DRUG REACTIONS CHAPTER 10 [8] Burrows J, Nissen L, Kirkpatrick C, Bell S. Beta-lactam allergy in adults with cystic fibrosis. J Cyst Fibros. 2007;6(4):297-303. [9] Roehmel JF, Schwarz C, Mehl A, Stock P, Staab D. Hypersensitivity to antibiotics in patients with cystic fibrosis. J Cyst Fibros. 2014;13(2):205- 11. [10] Scambler T, Jarosz-Griffiths HH, Lara- Reyna S, Pathak S, Wong C, Holbrook J, et al. ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis. Elife. 2019;8. [11] Peckham D, Scambler T, Savic S, McDermott MF. The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol. 2017;241(2):123-39. [12] Rimessi A, Bezzerri V, Patergnani S, Marchi S, Cabrini G, Pinton P. Mito- chondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudo- monas aeruginosa-driven inflamma- tory response in cystic fibrosis. Nat Commun. 2015;6:6201. [13] Ming L, Wen Q, Qiao HL, Dong ZM. Interleukin-18 and IL18-607A/C and-137G/C Gene Polymorphisms in Patients with Penicillin Allergy. Journal of International Medical Research. 2011;39(2):388-98. [14] Hector A, Schafer H, Poschel S, Fischer A, Fritzsching B, Ralhan A, et al. Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection. Am J Respir Crit Care Med. 2015;191(8):914-23. References [1] Davies DM. Textbook of adverse drug reactions. 4th ed. ed: Oxford Univer- sity Press; 1991. xiv,879p. p. [2] Gell PGHe, Coombs RRAe. Clinical aspects of immunology. 2nd ed. ed. [S.l.]: Blackwell; 1968. [3] Whitaker P, Meng X, Lavergne SN, El-Ghaiesh S, Monshi M, Earnshaw C, et al. Mass spectrometric character- ization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. Journal of immunology. 2011;187(1):200-11. [4] Elsheikh A, Castrejon L, Lavergne SN, Whitaker P, Monshi M, Callan H, et al. Enhanced antigenicity leads to altered immunogenicity in sulfame- thoxazole-hypersensitive patients with cystic fibrosis. J Allergy Clin Immunol. 2011;127(6):1543-51.e3. [5] Wills R, Henry R, Francis J. Antibiotic hypersensitivity reactions in cystic fibrosis. J Paediatr Child Health. 1998;34(4):325-9. [6] Pleasants R, Walker T, Samuelson W. Allergic reactions to paren- teral beta-lactam antibiotics in patients with cystic fibrosis. Chest. 1994;106(4):1124-8. [7] Koch C, Hjelt K, Pedersen S, Jensen E, Jensen T, Lanng S, et al. Retrospec- tive clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis. 1991;13 Suppl 7:S608-11.